Sacituzumab govitecan
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SACITUZUMAB-GOVITECAN |
|---|---|
| Type | Drug |
| Aliases | TrodelvyСацитузумаб говітекан |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Trop-2-targeted antibody-drug conjugate (SN-38 payload) |
|---|---|
| Mechanism | Anti-Trop-2 antibody linked to SN-38 (active metabolite of irinotecan, topoisomerase-I inhibitor). Trop-2 is overexpressed on most epithelial cancers; ADC delivers SN-38 selectively. |
| Typical dosing | 10 mg/kg IV days 1, 8 of 21-day cycle. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
ASCENT: sacituzumab superior to physician's-choice chemo in pretreated metastatic TNBC. TROPiCS-02: HR+/HER2- ≥3L. Trop-2 expression status not required for treatment selection (universal expression).
Used By
Regimens
REG-SACITUZUMAB- Sacituzumab govitecan monotherapy (TNBC ≥2L; HR+/HER2- ≥3L)